The project aimed to improve the availability of evidence-based migraine treatment by creating a fully digital and cost-effective digital headache clinic — a patient mobile application and a specialist dashboard connected to each other.

The main goal was to complement and improve previous developments — creating more secure and scalable authentication and identification options, increasing product quality, and onboarding first real-life healthcare service provider users.

• Previously developed solutions: complementation and improvement
• Higher security and better scalability
• Better authentication and identification options
• Increased quality of the product
• First real-life healthcare service providers as users

Migrevention OÜ — established in 2020 as a need-driven digital health company. The team consists of diverse migraine experts from patients to Estonia's top medical specialists. The main product is a digital headache clinic based on the International Headache Standard and multidisciplinary headache treatment approach.

Quretec OÜ — established in 2006 as a software company specialising in data management solutions, bioinformatics and biostatistics. Has provided innovative software development and data management services since 2006.

The Connected Health cluster is based on three operational objectives:

• Increasing the cluster's global visibility and international sales of cluster companies through coordinated joint development, marketing and sales activities
• Methodical contribution to the emergence of scalable value-based products and services by bringing together developers and necessary partners and initiating the required test environments and IT infrastructure
• Cultivating the management and sales ability of entrepreneurs and employees in the field of health and contributing to the training of specialists

Migrevention was lead partner in three joint development projects co-financed by the European Regional Development Fund:

• Migrevention digital headache clinic — phase I · Partner: Quretec OÜ · Co-financing: 25 000 EUR
• Migrevention digital distance treatment platform · Partner: Quretec OÜ · Co-financing: 25 000 EUR
• Creating the eHL-Migrevention interface · Partners: Quretec OÜ, SA Tartu University Hospital, Nortal AS · Co-financing: 25 000 EUR

Financed from the state budget from the means of financing research and development activities.

Migrevention's wider vision for the UK market is for the digital headache clinic solution to be recognised by the NHS as a best practice standard and to be widely adopted across the UK healthcare system — at least 25% of relevant NHS hospitals and clinics by 2029.

The purpose of this business model testing project was to carry out the necessary prerequisite activities that would ensure market access and provide an opportunity for a full-scale launch of the product in the UK healthcare system in 2025.

• Carrying out the initial validation of the product in the UK market in a clinical environment (service evaluation process)
• Developing a sales strategy and sustainable growth model for active expansion across the NHS network
• Conducting a Product Technology Assessment (DTAC) process in the UK for regulatory approval

The project aims to develop a Minimum Viable Product (MVP) for a new Digital Chronic Pain Clinic — a working patient mobile application and specialist dashboard supporting chronic pain self-management, remote monitoring and multidisciplinary care.

The project is carried out by Migrevention OÜ in cooperation with Viljandi Hospital and Tartu University Hospital. It builds on Migrevention's previous experience in developing digital clinic pathways and applies this knowledge to the needs of chronic pain patients and specialists.

The expected result is a clinically informed MVP that creates the basis for further product development, validation and future Software-as-a-Medical Device certification. The project supports Migrevention's wider goal of building evidence-based digital care pathways for chronic pain management.

Migrevention OÜ — a deep-tech digital health company developing software-based medical device solutions and data-driven digital clinic pathways.

SA Viljandi Haigla — an Estonian hospital and clinical innovation partner contributing expertise in chronic pain care, rehabilitation and digitally enabled care models.

SA Tartu Ülikooli Kliinikum — Estonia's largest university hospital and a clinical research partner contributing expertise in pain management, rehabilitation and digital health validation.

Projekti eesmärk on arendada uue digitaalse kroonilise valu kliiniku minimaalne töötav toode ehk MVP — toimiv patsiendi mobiilirakendus ja spetsialisti töölaud, mis toetavad kroonilise valu enesejuhtimist, kaugjälgimist ja multidistsiplinaarset ravi.

Projekti viib ellu Migrevention OÜ koostöös Viljandi Haigla ja Tartu Ülikooli Kliinikumiga. Projekt tugineb Migreventioni varasemale kogemusele digitaalsete raviteekondade arendamisel ning rakendab seda teadmist kroonilise valu patsientide ja spetsialistide vajadustele.

Oodatav tulemus on kliinilisel sisendil põhinev MVP, mis loob aluse edasiseks tootearenduseks, valideerimiseks ja tulevaseks Software-as-a-Medical Device ehk tarkvaralise meditsiiniseadmena sertifitseerimiseks. Projekt toetab Migreventioni laiemat eesmärki arendada tõenduspõhiseid digitaalseid raviteekondi kroonilise valu käsitluseks.

Migrevention OÜ — süvatehnoloogia digitaalsete terviselahenduste ettevõte, mis arendab tarkvaralisi meditsiiniseadmeid ja andmepõhiseid digitaalseid raviteekondi.

SA Viljandi Haigla — Eesti haigla ja kliinilise innovatsiooni partner, kes panustab projekti kroonilise valu käsitluse, taastusravi ja digitaalselt toetatud ravimudelite ekspertiisiga.

SA Tartu Ülikooli Kliinikum — Eesti suurim ülikoolihaigla ja kliinilise teadustöö partner, kes panustab projekti valuravi, taastusravi ja digitaalsete terviselahenduste valideerimise ekspertiisiga.